Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Turkey / NCT01878344
Active, not recruiting Phase 3

Effects of N-acetyl Cysteine During Primary Percutaneous Coronary Intervention

NCT01878344 · tracked via the Priya Life Science Turkey tracker
Sponsor
Suleyman Demirel University
Phase
Phase 3
Started
2013-01
Last updated
2025-05-20

Condition(s) studied

Acute ST Segment Elevation Myocardial Infarction

Investigational drug(s) / intervention(s)

NACSaline

Study summary

The aim of this study is to evaluate the effects of N-acetyl cysteine on major cardiac and cerebral events in patients undergoing primary percutaneous coronary intervention who have moderate to high risk for contrast induced nephropathy.

In a sub-group of patients coronary flow reserve will be evaluated.

Eligibility

Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria: * Patients with Acute ST Elevation Myocardial Infarction undergoing Primary Percutaneous Coronary intervention Who Have Moderate to High Risk For Contrast Induced Nephropathy (Mehran Score ≥5) Exclusion Criteria: * Patients \>18 years old with moderate to high risk for contrast induced nephropathy undergoing percutaneous coronary intervention * Low risk for contrast induced nephropathy (Mehran Score \<5) * Use of nephrotoxic agents (NSAIDs, aminoglycosides,recent contrast injection...) * Infection * Pregnancy, Lactation * Renal failure requiring dialysis * Hepatic failure * Allergy to NAC * History of Asthma * Chronic nitrate usage * Malignancy * Use of corticosteroids * Leucocytosis,Thrombocytosis,Anemia * Blood pressure of \>180/100mmHg despite anti-hypertensive therapy

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Suleyman Demirel University Isparta Mediterranean Region

More Suleyman Demirel University trials in Turkey

Sandplay-Act. Older: Structured Sandplay Activity for Older Individuals Starting soon
Relationship Between Cervical Pain According to Cervical Proprioceptive Awareness Level in the Healthy Elderly Enrolling by invitation
Salivary Biomarkers in Periodontal Disease Progression Recruiting
Somatosensory Amplification and Psychological and Functional Status In Patients With Knee Osteoarthritis Recruiting
Effects of N-acetyl Cysteine During Percutaneous Coronary Intervention Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT01878344 on ClinicalTrials.gov ↗ ← All trials in Turkey